Corcept Therapeutics (CORT) affiliate files to sell 40,000 shares after option exercise

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) affiliate Atabak Mokari filed a notice to sell 40,000 shares of common stock through Stifel Nicolaus & Company on or about July 30, 2026 on Nasdaq. The shares relate to stock option exercises dated February 13, 2023 under equity compensation.

The filing also lists prior sales over the past three months: 40,000 shares on June 1, 2026 for $2,800,004.00, 40,000 shares on June 15, 2026 for $3,245,900.00, and 40,000 shares on July 15, 2026 for $3,508,276.00.

Key Figures

Planned shares to be sold: 40,000 shares Shares sold June 1, 2026: 40,000 shares Proceeds June 1, 2026: $2,800,004.00 +3 more

6 metrics

Planned shares to be sold 40,000 shares Common stock to be sold on or about July 30, 2026

Shares sold June 1, 2026 40,000 shares Common stock sold on June 1, 2026

Proceeds June 1, 2026 $2,800,004.00 Aggregate sale price for 40,000 shares on June 1, 2026

Proceeds June 15, 2026 $3,245,900.00 Aggregate sale price for 40,000 shares on June 15, 2026

Proceeds July 15, 2026 $3,508,276.00 Aggregate sale price for 40,000 shares on July 15, 2026

Option exercise date 02/13/2023 Date of stock option exercises underlying the 40,000 shares

Key Terms

Form 144, Stock Option Exercises, Equity Compensation

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Stock Option Exercises financial

"Common Stock | 02/13/2023 | Stock Option Exercises | Issuer"

Equity Compensation financial

"40000 | 02/13/2023 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 04:05 PM Accepted by SEC EDGAR 07/30/2026 - 04:03 PM Learn about SEC filing dates

FAQ

What does Corcept Therapeutics (CORT) Form 144 filed by Atabak Mokari disclose?

The Form 144 discloses Atabak Mokari’s proposed sale of 40,000 shares of Corcept Therapeutics common stock on or about July 30, 2026, with the shares tied to stock option exercises from February 13, 2023.

How many Corcept Therapeutics (CORT) shares is Atabak Mokari planning to sell?

Atabak Mokari plans to sell 40,000 shares of Corcept Therapeutics common stock. These shares are associated with equity compensation arising from stock option exercises that occurred on February 13, 2023.

Which broker will handle the Corcept Therapeutics (CORT) Form 144 sale for Atabak Mokari?

The Form 144 states that Stifel Nicolaus & Company Inc., located at 501 N Broadway, St. Louis, MO 63102, will handle the planned sale of 40,000 shares of Corcept Therapeutics common stock on Nasdaq.

What prior Corcept Therapeutics (CORT) stock sales by Atabak Mokari are listed in the Form 144?

The filing lists three prior sales: 40,000 shares on June 1, 2026 for $2,800,004.00, 40,000 shares on June 15, 2026 for $3,245,900.00, and 40,000 shares on July 15, 2026 for $3,508,276.00.

What is the nature of the Corcept Therapeutics (CORT) shares in Atabak Mokari’s Form 144?

The 40,000 shares to be sold are Corcept Therapeutics common stock obtained via stock option exercises dated February 13, 2023, categorized in the filing as equity compensation from the issuer.

On which market will the Corcept Therapeutics (CORT) Form 144 shares be sold?

The Form 144 specifies that the 40,000 shares of Corcept Therapeutics common stock are expected to be sold on the Nasdaq market, with Stifel Nicolaus & Company Inc. acting as the broker.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	40000	4588556.00	108098397	07/30/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/13/2023	Stock Option Exercises	Issuer			40000	02/13/2023	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atabak Mokari 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 64065	Common Stock	06/01/2026	40000	2800004.00
Atabak Mokari 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065	Common Stock	06/15/2026	40000	3245900.00
Atabak Mokari 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065	Common Stock	07/15/2026	40000	3508276.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)